Keros Therapeutics (KROS) Other Non-Current Assets (2019 - 2025)

Keros Therapeutics has reported Other Non-Current Assets for 7 years, with the latest figure at $1.4 million in Q3 2025.

• For the quarter ending Q3 2025, Other Non-Current Assets changed 0.0% year-over-year to $1.4 million; the trailing twelve-month figure through Sep 2025 stood at $1.4 million (changed 0.0% YoY), and the FY2024 full-year result was $1.4 million, up 20.75% from the prior year.
• Other Non-Current Assets for Q3 2025 stood at $1.4 million, up from $463000.0 in the prior quarter.
• The five-year high for Other Non-Current Assets was $1.4 million in Q3 2024, with the low at $115000.0 in Q1 2021.
• Historically, Other Non-Current Assets has averaged $1.1 million across 5 years, with a median of $1.3 million in 2021.
• Annual changes were most pronounced in 2021 — Other Non-Current Assets soared 1054.78% — and 2025, when it sank 61.8%.
• Keros Therapeutics' Other Non-Current Assets stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then dropped by 9.57% to $1.2 million in 2023, then increased by 20.75% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
• The last three Other Non-Current Assets figures came in at $1.4 million (Q3 2025), $463000.0 (Q1 2025), and $1.4 million (Q4 2024), per Business Quant data.